The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Jazz Pharmaceuticals (NASDAQ:JAZZ) is one of the most undervalued biotech stocks to buy right now. On April 10, Raymond James resumed coverage of Jazz Pharmaceuticals (NASDAQ:JAZZ) with an Outperform rating and set a price target of $227. The firm told investors that the Jazz story has travelled beyond the narrative of “it looks inexpensive/fairly valued, but where can I get upside?” since adding greater visibility to the tail value of the Epidiolex franchise and zanidatamab delivering “highly competitive” data in gastroesophageal adenocarcinoma.

Jazz Pharmaceuticals (NASDAQ:JAZZ) also received a rating update from Piper Sandler on March 19, with the firm lifting the price target on the stock to $232 from $219 while maintaining an Overweight rating on the shares. The firm stated that moving further into 2026, it continues to view the company as undervalued at a current EV/2026E EBITDA of only seven times in the context of a company that has strong visibility into double-digit overall top-line growth starting in 2027. Piper added that the competitive dynamics associated with the oxybate franchise are not lost on it, but it does not envision said dynamics throwing a wrench into its thinking regarding Jazz Pharmaceuticals’ (NASDAQ:JAZZ) overall growth profile.

Jazz Pharmaceuticals (NASDAQ:JAZZ) develops medicines for serious diseases. Its primary marketed products include Xywav, Xyrem oral solution, Epidiolex oral solution, Rylaze, Zepzelca, Defitelio, and Vyxeos liposome for injection. These medicines treat excess daytime sleepiness (EDS) in narcolepsy patients seven years of age or older, tepatic veno-occlusive disease (VOD), and other ailments.

While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.